Hospital Gemeinschaftskrankenhaus Havelhöhe, Research Institute Havelhöhe, Kladower Damm 221, 14089, Berlin, Germany.
Interdisciplinary Oncology and Palliative Care, Hospital Gemeinschaftskrankenhaus Havelhöhe, Berlin, Germany.
Radiat Oncol. 2023 Mar 6;18(1):47. doi: 10.1186/s13014-023-02234-3.
Lung cancer (LC) is associated with high mortality and poor quality of life (QoL). The disease as well as oncological treatments such as radiation and chemotherapy with adverse effects can impair the QoL of patients. Add-on treatment with extracts of Viscum album L. (white-berry European mistletoe, VA) has been shown to be feasible and safe and to improve the QoL of cancer patients. The aim of this study was to analyze the changes in QoL of LC patients being treated with radiation according to oncological guidelines and add-on VA treatment in a real-world setting.
A real-world data study was conducted using registry data. Self-reported QoL was assessed by the evaluation of the European Organization of Research and Treatment Health-Related Quality of Life Core Questionnaire scale (EORTC QLQ-C30). Adjusted multivariate linear regression analyses were performed to analyze factors associated with changes in QoL at 12 months.
A total of 112 primary LC patients (all stages, 92% non-small-cell lung cancer, median age 70 (ICR: 63-75)), answered the questionnaires at first diagnosis and 12 months later. Assessment of 12 months changes in QoL revealed significant improvement of 27 points for pain (p = 0.006) and 17 points for nausea/vomiting (p = 0.005) in patients who received combined radiation and VA. In addition, significant improvements of 15 to 21 points for role (p = 0.03), physical (p = 0.02), cognitive (p = 0.04), and social functioning (p = 0.04) were observed in guideline treated patients receiving no radiation but add-on VA.
Add-on VA therapy reveals supportive effects for the QoL of LC patients. Particularly in combination with radiation a significant reduction in pain and nausea/ vomiting has been observed. Trial registration The study received ethics approval and was retrospectively registered (DRKS00013335 on 27/11/2017).
肺癌（LC）死亡率高，生活质量（QoL）差。疾病以及放射治疗和化疗等抗肿瘤治疗的不良反应会损害患者的 QoL。白浆果欧洲槲寄生（VA）提取物的附加治疗已被证明是可行且安全的，并能改善癌症患者的 QoL。本研究旨在分析根据肿瘤学指南对接受放射治疗的 LC 患者进行的附加 VA 治疗后 QoL 的变化。
使用登记数据进行真实世界数据研究。通过欧洲癌症研究与治疗组织健康相关生活质量核心问卷量表（EORTC QLQ-C30）评估自我报告的 QoL。进行调整后的多元线性回归分析，以分析与 12 个月时 QoL 变化相关的因素。
共有 112 例原发性 LC 患者（所有阶段，92%非小细胞肺癌，中位年龄 70（ICR：63-75）），在首次诊断时和 12 个月后回答了问卷。对 12 个月 QoL 变化的评估显示，接受联合放疗和 VA 治疗的患者疼痛改善 27 分（p = 0.006），恶心/呕吐改善 17 分（p = 0.005）。此外，在接受 VA 附加治疗但未接受放疗的指南治疗患者中，角色功能（p = 0.03）、躯体功能（p = 0.02）、认知功能（p = 0.04）和社会功能（p = 0.04）分别改善了 15 至 21 分。
VA 附加治疗对 LC 患者的 QoL 具有支持作用。特别是与放射治疗联合使用，疼痛和恶心/呕吐明显减轻。
该研究获得了伦理批准，并进行了回顾性注册（DRKS00013335，于 2017 年 11 月 27 日）。
